share_log

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

Moomoo 24/7 ·  Mar 1 07:10

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment